Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Jornay PM is a prescription CNS stimulant containing methylphenidate hydrochloride, approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 and older. What makes Jornay PM unique is its evening dosing schedule — you take it at night, and it delivers therapeutic levels of methylphenidate the following morning, providing symptom control throughout the day. This is especially helpful for patients who struggle with early-morning ADHD symptoms like difficulty getting ready for school or work. It is manufactured by Collegium Pharmaceutical.
Jornay PM uses a delayed-release, extended-release (DR/ER) bead technology. When taken in the evening, less than 5% of the medication is absorbed in the first 10 hours. The drug then releases methylphenidate the following morning, blocking the reuptake of norepinephrine and dopamine in the brain. By increasing these neurotransmitter levels, Jornay PM improves attention, focus, and impulse control. The delayed-release mechanism means patients wake up with the medication already working — a key advantage over morning-dosed stimulants.
All strengths are delayed-release, extended-release capsules designed for evening dosing between 6:30 PM and 9:30 PM.
Jornay PM receives a findability score of 55 out of 100, meaning it can be intermittently difficult to locate. As a brand-only, niche ADHD medication with evening dosing, many retail pharmacies do not routinely stock it. While Jornay PM is not on the FDA's active shortage list, the broader stimulant shortage affecting methylphenidate products since 2022 has made supply less predictable. Patients often have better luck at specialty pharmacies or by using Medfinder to check stock in real time.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
As a Schedule II controlled substance, Jornay PM must be prescribed by a licensed physician, nurse practitioner, or physician assistant with prescriptive authority. Common prescribing specialties include:
Because Jornay PM is a niche formulation, some general practitioners may be less familiar with it. Patients may need to see an ADHD specialist to get a prescription.
Yes. Jornay PM is classified as a Schedule II (CII) controlled substance by the DEA, the same category as other methylphenidate and amphetamine products. This means it has a high potential for abuse and dependence. Prescriptions cannot be called in to pharmacies in most states and typically require a new written or electronic prescription each month. The FDA boxed warning states that CNS stimulants including Jornay PM can lead to substance use disorder, including addiction, and misuse can result in overdose and death.
Serious side effects can include heart attack, stroke, sudden death in patients with heart conditions, new psychiatric symptoms (mania, psychosis), priapism, and Raynaud's phenomenon. Contact your doctor immediately if you experience chest pain, shortness of breath, or severe mood changes.
If you're having trouble finding or affording Jornay PM, talk to your doctor about these alternatives. Use Medfinder to check availability near you.
Jornay PM fills a unique niche in ADHD treatment as the only evening-dosed methylphenidate, making it ideal for patients who need symptom control first thing in the morning. However, its brand-only status means higher costs ($340–$620/month without insurance) and limited pharmacy stocking. No generic is expected until 2032. If your insurance covers it, the manufacturer savings card at jornaypm.com/savings can bring copays down to $75/month. For help finding Jornay PM in stock near you, try Medfinder to search pharmacies in real time instead of calling around.
%2C%20Color%3DOriginal.png)
